Mylan and two Indian companies are in the race to acquire the company, which makes haemoglobin drug 'Raricap' among other products.

Stock-specific action is expected in the following stocks on the back of newsflow.

Deal size likely to be around 1.7% of the company's annual revenue; sale to help Chennai-based drug maker get rid of its Rs 100-crore debt.

Bafna Pharmaceuticals today said it has launched pain management and anti-infective products in the domestic market.

The Board of Directors of Bafna Pharmaceuticals at its meeting held on May 20, 2013 have recommended 6% dividend.